Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.

Klemen Dovc¹, Claudia Piona², Gül Yeşiltepe Mutlu³, Natasa Bratina¹, Barbara Jenko Bizjan¹, Dusanka Lepej⁴, Revital Nimri⁵, Eran Atlas⁶, Ido Muller⁶, Olga Kordonouri⁷, Torben Biester⁷, Thomas Danne⁷, Moshe Phillip^5,8, Tadej Battelino^9,10

¹Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre-University Children's Hospital, Ljubljana, Slovenia.

²Pediatric Diabetes and Metabolic Disorders Unit, University City Hospital, Verona, Italy.

³Department of Pediatric Endocrinology and Diabetes, Koç University Hospital, İstanbul, Turkey.

⁴Department of Pulmonology, University Medical Centre-University Children's Hospital, Ljubljana, Slovenia.

⁵The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Centre for Childhood Diabetes, Schneider Children's Medical Centre of Israel, Petah Tikva, Israel.

⁶DreaMed Diabetes Ltd., Petah Tikva, Israel.

⁷Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany.

⁸Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

⁹Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre-University Children's Hospital, Ljubljana, Slovenia tadej.battelino@mf.uni-lj.si.

¹⁰Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

PubMed DOI

Abstract

OBJECTIVE: We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 ± 2.3 years, HbA1c 7.5 ±…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.